Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer (Q38971107)

8 September 2017

title

Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer (English)

1 reference

8 September 2017

0 references

sesquiterpene lactone

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Bo Xiao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Saravanan Ayyadurai

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Lixin Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Peng G Wang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Quan Zhang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Yue Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Didier Merlin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

28 July 2014

1 reference

8 September 2017

published in

Laboratory Investigation

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

950-965

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Experimental inflammatory bowel disease: insights into the host-microbiota dialog

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Genetics and pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Inflammation and colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Ethnopharmacology of Mexican asteraceae (Compositae).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

The solution and solid state stability and excipient compatibility of parthenolide in feverfew

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Biomimetic semisynthesis of arglabin from parthenolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

The application of Heck reaction in the synthesis of guaianolide sesquiterpene lactones derivatives selectively inhibiting resistant acute leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Synthesis of micheliolide derivatives and their activities against AML progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

ADAM-15 inhibits wound healing in human intestinal epithelial cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Gastrointestinal delivery of anti-inflammatory nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

The effect of capsule composition on the biocompatibility of alginate-poly-1-lysine capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Crosslinked chitosan implants as potential degradable devices for brachytherapy: in vitro and in vivo analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Therapeutic potential of chitosan and its derivatives in regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Role of cytokines in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Tumor necrosis factor family members and inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Optimizing anti-TNF treatment in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Infliximab therapy in pediatric Crohn's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2014.89

Toll-like receptor 9-induced type I IFN protects mice from experimental colitis

21 January 2018

1 reference

12 December 2020

Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR

1 reference

12 December 2020

Cloning of a lymphatic peptide/histidine transporter

1 reference

12 December 2020

Mechanisms in failure of infliximab for Crohn's disease

1 reference

12 December 2020

Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study

1 reference

12 December 2020

NF-κB pathway in colitis-associated cancers

1 reference

12 December 2020

Severe neutropenia following infliximab treatment in a child with ulcerative colitis

1 reference

12 December 2020

Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates dextran sulfate sodium-induced colitis in mice

1 reference

12 December 2020

Hyaluronan and wound healing: a new perspective

1 reference

12 December 2020

Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta

1 reference

12 December 2020

Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity

1 reference

12 December 2020

10.1038/LABINVEST.2014.89

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

31 May 2020

1003594579

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25068660%20AND%20SRC:MED&resulttype=core&format=json